While Corbion N.V. (AMS:CRBN) might not be the most widely known stock at the moment, it received a lot of attention from a substantial price movement on the ENXTAM over the last few months, increasing to €30.40 at one point, and dropping to the lows of €21.06. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Corbion's current trading price of €22.24 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Corbion’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
Check out our latest analysis for Corbion
Is Corbion Still Cheap?
According to my valuation model, Corbion seems to be fairly priced at around 4.62% above my intrinsic value, which means if you buy Corbion today, you’d be paying a relatively fair price for it. And if you believe the company’s true value is €21.26, then there isn’t really any room for the share price grow beyond what it’s currently trading. In addition to this, Corbion has a low beta, which suggests its share price is less volatile than the wider market.
Can we expect growth from Corbion?
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Corbion's earnings over the next few years are expected to increase by 23%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.
What This Means For You
Are you a shareholder? CRBN’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?
Are you a potential investor? If you’ve been keeping tabs on CRBN, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.
If you'd like to know more about Corbion as a business, it's important to be aware of any risks it's facing. To help with this, we've discovered 3 warning signs (2 can't be ignored!) that you ought to be aware of before buying any shares in Corbion.
If you are no longer interested in Corbion, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTAM:CRBN
Corbion
Provides lactic acid and lactic acid derivatives, other ferment, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide.
Solid track record, good value and pays a dividend.